A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema

Part of paid clinical trials in Tulsa, Oklahoma.

Sponsor: Pfizer
Study ID: NCT07783425
Phase: PHASE3
Status: Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Atopic Dermatitis

Eligibility Criteria

Sex: ALL
Age: 12 Years - N/A
Healthy Volunteers: Not accepted

Interventions

Tilrekimig — DRUG
Subcutaneous Injections at required timepoints
Dupilumab — DRUG
Subcutaneous Injections at required timepoints based on weight and age.
Placebo for Tilrekimig — OTHER
Subcutaneous Injections at required timepoints
Placebo for Dupilumab — OTHER
Subcutaneous Injections at required timepoints during initial treatment period.

Study Details

The purpose of this study is to find out how well tilrekimig works, how safe it is, and how it affects the body in adults and adolescents with moderate to severe atopic dermatitis (eczema). Eczema is a condition which can cause dryness, itching, and redness of your skin. The study is seeking participants who: * Are aged 12 years or older. * Were confirmed to have atopic dermatitis (AD) at least 12 months ago. * Are not having an effective treatment result from medicines that are applied on skin for AD. * Are considered by their doctors to have moderate to severe AD. The study treatment period will be 52 weeks. During the 24-week initial treatment period, participants will be randomized to one of three study treatments - tilrekimig, dupilumab, or placebo. Placebo does not have any medicine in it but looks just like the medicine being studied. These treatments will be randomized based on a 2:2:1 ratio. This means out of 1375 participants, about 550 participants will receive tilrekimig, 550 will receive dupilumab, and 275 will receive placebo. This will be followed by a 28-week maintenance period. The last dose of study treatment will be administered at week 48. Some participants will join the long-term extension (LTE) study C4531008 at week 52. A long-term extension study is an additional study that some participants may be able to join after completing the study if they are interested and meet eligibility requirements. It allows researchers to continue collecting information about how well the study medicine works. It also helps them assess how safe it is when used for a longer period of time. Participants who do not join this study will enter a 12-week safety follow-up period. This period ends 16 weeks after their last dose of study treatment.

Key Dates

First listed: Aug 24, 2026
Start date: Aug 19, 2026
Status verified: Aug 2026
Primary completion: Aug 29, 2028
Completion: Jun 5, 2029

Study Design

Enrollment: 1,375 participants (estimated)
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Arms

Experimental: Tilrekimig - Initial treatment period
Subcutaneous injections given over 20 Weeks.
Active Comparator: Dupilumab - Initial treatment period
Subcutaneous injections given over 22 Weeks.
Placebo Comparator: Placebo - Initial treatment period
Subcutaneous injections given over 22 Weeks.
Experimental: Tilrekimig - Maintenance Period - Dose A
Subcutaneous injections given at Week 24 through Week 48.
Experimental: Tilrekimig - Maintenance Period - Dose B
Subcutaneous injections given at Week 24 through Week 48.
Placebo Comparator: Placebo - Maintenance Period
Subcutaneous injections given at Week 24 through Week 48.